Karin Havenith
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 31
- CAR-T cell therapy research 21
- HER2/EGFR in Cancer Research 10
-
- Cancer therapeutics and mechanisms 8
- Co-authors
- Jay Feingold (8 shared papers)Mehdi Hamadani (11 shared papers)Paolo F. Caimi (10 shared papers)John Radford (4 shared papers)David Ungar (4 shared papers)Melhem Solh (4 shared papers)Brad S. Kahl (4 shared papers)Carmelo Carlo‐Stella (9 shared papers)
- Journals
- Cancer Research (12 papers)Blood (8 papers)Hematological Oncology (3 papers)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Karin Havenith
38 papers receiving 906 citations
Karin Havenith's Hit Papers
Peers
Comparison fields: 5 of 52
- Oncology 671
- Pathology and Forensic Medicine 371
- Genetics 117
- Radiology, Nuclear Medicine and Imaging 214
- Immunology 172
Countries citing papers authored by Karin Havenith
This map shows the geographic impact of Karin Havenith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Havenith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Havenith more than expected).
Fields of papers citing papers by Karin Havenith
This network shows the impact of papers produced by Karin Havenith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Havenith. The network helps show where Karin Havenith may publish in the future.
Co-authors
The 25 scholars most cited alongside Karin Havenith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 284 |
| 2 | 2020 | 132 | |
| 3 | 2019 | 82 | |
| 4 | 2021 | 68 | |
| 5 | 2020 | 61 | |
| 6 | 1997 | 44 | |
| 7 | 2020 | 42 | |
| 8 | 2020 | 31 | |
| 9 | Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers | 2022 | 29 |
| 10 | 1997 | 18 | |
| 11 | 2016 | 14 | |
| 12 | 2016 | 12 | |
| 13 | 1995 | 11 | |
| 14 | 2015 | 9 | |
| 15 | 2024 | 8 | |
| 16 | 2017 | 8 | |
| 17 | 2024 | 8 | |
| 18 | 2017 | 7 | |
| 19 | 2015 | 6 | |
| 20 | 2018 | 5 |
About Karin Havenith
Karin Havenith is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Immunology, having authored 41 papers that have together received 926 indexed citations. Recurring topics across this work include CAR-T cell therapy research (21 papers), HER2/EGFR in Cancer Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Synthesis and pharmacology of benzodiazepine derivatives (6 papers), Neuroblastoma Research and Treatments (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). The work is most often cited by research in Oncology (671 citations), Pathology and Forensic Medicine (371 citations), Genetics (117 citations), Radiology, Nuclear Medicine and Imaging (214 citations) and Immunology (172 citations). Karin Havenith has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Jay Feingold, Mehdi Hamadani, Paolo F. Caimi, John Radford, David Ungar, Melhem Solh, Brad S. Kahl, Carmelo Carlo‐Stella, Kirit M. Ardeshna and Yajuan Qin. Their work appears in journals such as Cancer Research, Blood, Hematological Oncology, Molecular Cancer Therapeutics and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.